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The purpose of this study was to evaluate the maximum tolerated dose (MTD) and recommended dose of oxaliplatin given
synchronously with 5-fluorouracil (5FU), leucovorin (LV) and preoperative pelvic radiation for primary unresectable, locally advanced,
rectal cancer. Preoperative pelvic radiotherapy using a three- or four-field technique and megavoltage photons comprised 45Gy
given in 25 fractions, 1.8Gy per fraction, and delivered with escalating doses of oxaliplatin in combination with low-dose LV and 5FU.
Chemotherapy was given synchronously with radiotherapy in weeks 1 and 5. Escalating doses of oxaliplatin (85, 130 and 150mgm
 2)
were given on days 2 and 30, followed by low-dose LV (20mgm
 2) and 5FU (350mgm
 2), both given on days 1–5 and 29–33.
Surgery was performed 6–10 weeks later. The MTD was determined as the dose causing more than a third of patients to have a
dose-limiting toxicity (DLT). Once the MTD was reached, a further 14 patients were treated at the dose level below the MTD. In all,
32 patients received oxaliplatin at the three dose levels, median age 60 years (range 31–79), 24 males and eight females. The MTD
was reached at 150mgm
 2 when four out of six patients experienced DLT. Dose-limiting grade 3 or 4 diarrhoea was reported in
two out of six patients at 85mgm
 2, 5 out of 20 at 130mgm
 2 and four out of 6 at 150mgm
 2. Grade 3 neuropathy was reported
at 130mgm
 2 (1 out of 20) and at 150mgm
 2 (two out of six), and serious haematological toxicity was minimal; one grade 3
anaemia at 150mgm
 2. In all, 28 out of 32 patients completed all treatments as planned; three had radiotherapy interrupted and
three a chemotherapy dose reduction. Four patients did not proceed to surgery due to the presence of metastatic disease (two),
unfitness (one) or patient refusal (one). Also, 28 patients underwent surgical resection. Histopathology demonstrated
histopathological complete response (pCR) 2 out of 27 (7%), Tmic 3 out of 27 (11%), pCRþTmic 5 out of 27 (19%), pT0–2 6
out of 27 (22%) and histologically confirmed clear circumferential resection margins in 22 out of 27 (81%). Dose-limiting toxicity with
oxaliplatin is 150mgm
 2 given days 2 and 30 when added to the described 5FU LV and 45Gy radiation preoperatively. The
acceptable toxicity and compliance at 130mgm
 2 recommend testing this dose in future phase II studies. The tumour downstaging
and complete resection rates are encouragingly high for this very locally advanced group.
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A curative surgical resection remains the most important
component of the modern multimodality management of rectal
cancer. However, randomised controlled trials (Swedish Rectal
Cancer Trial, 1997; Kapiteijn et al, 2001; Sauer et al, 2004) and two
meta-analyses (Camma ` et al, 2000; Colorectal Cancer Collaborative
Group, 2001) have also demonstrated that adjuvant radiation can
reduce the rate of locoregional recurrence, although its impact on
overall survival is less clear. The meta-analyses show greater
benefit for preoperative radiotherapy treatment.
Recent advances that have improved the outcome in rectal
cancer include a more radical surgical technique incorporating
mesorectal excision (Enker et al, 1995, Heald et al, 1998) and a
more accurate histopathological examination of the resected
specimen, reporting the proximity of microscopic tumour to the
circumferential resection margin (CRM) (Quirke et al, 1986).
Individual surgical series, a population-based audit (Wibe et al,
2002) and evidence from a randomised controlled trial (Nagtegaal
et al, 2002), all demonstrate lower rates of local recurrence
following mesorectal excision compared with the previous
randomised trials that included a surgery alone arm. In addition,
involvement of the CRM is associated with a significantly increased
risk of local recurrence and also metastatic disease.
There is an increasing use of preoperative chemoradiation
(CRT) in patients with locally advanced rectal cancer, despite the
fact that there are few trials that have compared preoperative CRT
Received 27 July 2005; revised 19 September 2005; accepted 20
September 2005
*Correspondence: Dr D Sebag-Montefiore;
E-mail: David.Sebag-Montefiore@leedsth.nhs.uk
British Journal of Cancer (2005) 93, 993–998
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
swith radiation alone (Frykholm et al, 2001; Bosset et al, 2004). The
aims of treatment are to reduce the extent of the primary tumour
to allow macroscopic removal to take place, treat potential
microscopic disease close to or beyond the mesorectal fascia
and, if present, also treat micrometastatic disease outside the
radiation fields.
Most CRT schedules in current use combine pelvic radiation
with either continuous infusion 5-fluorouracil (5FU) or 5FU
modulated by leucovorin (LV). Mature results from the EORTC
22921 and FFCD 9203 trials of operable T3/T4 rectal cancer have
recently demonstrated a convincing reduction in locoregional
failure when a CRT regimen of 5FU and LV (as used in this study)
is added to 45Gy of pelvic radiation (Bosset et al, 2004, 2005;
Gerard et al, 2005). Phase III trials in metastatic colorectal cancer
have demonstrated statistically significant improvements in the
overall response rate and progression-free survival when oxalipla-
tin is added to a combination of 5FU LV (de Gramont et al, 2000;
Grothey, 2002; Goldberg et al, 2004). In the adjuvant setting, the
addition of oxaliplatin to 5FU LV significantly improves disease-
free survival (DFS) (Andre ´ et al, 2004). As the EORTC 22921 and
FFCD 9203 trials used 5FU LV-based CRT schedules, it was a
logical step to develop preoperative radiation schedules that
incorporate the addition of oxaliplatin to this regimen. The choice
of the 5FU LV regimen required the oxaliplatin to be given in
weeks 1 and 5 to ensure concomitant administration.
Oxaliplatin is also recognised to have radiosensitising effects in
both cell cultures and mouse xenografts. In preclinical models of
combined radiotherapy and oxaliplatin, an 8-h oxaliplatin
exposure was associated with a dose-related cell kill rate (Black-
stock et al, 2002). Synergistic effects with radiation were observed
when oxaliplatin was given both before and after radiation. In
mouse xenograft models of colorectal cancer, tumour growth has
been shown to be inhibited by combined oxaliplatin and radiation
(Blackstock et al, 2000).
The present study aimed to evaluate the addition of two doses of
oxaliplatin 4 weeks apart to a regimen of CRT that uses folinic acid
and 5FU daily during the first and fifth weeks of pelvic radiation
(45Gy), as used in the EORTC 22921 and FFCD 9203 phase III
trials (Bosset et al, 2004; Gerard et al, 2005).
PATIENTS AND METHODS
Study design
This dose escalation study aimed to increase the dose of oxaliplatin
given on days 2 and 30 in successive cohorts when added to a CRT
regimen consisting of low-dose LV and a short infusion of 5FU
administered concurrently with radiation until the maximum
tumour dose was reached. All patients received radiotherapy
(45Gy) with LV (20mgm
 2) and 5FU (350mgm
 2 administered
over 1h) on days 1–5 and 29–33 (see Figure 1). There were four
planned oxaliplatin dose levels, each consisting of six patients.
Oxaliplatin was administered in 250ml dextrose over 2h on days 2
and 30 (85, 130, 150, 170mgm
 2). Dose-limiting toxicities (DLTs)
were defined to include grade III or IV diarrhoea, nausea,
vomiting, thrombocytopaenia and neutropaenia according to the
National Cancer Institute Canada common toxicity criteria revised
1994 definitions and grade III acute sensorimotor neuropathy (i.e.
functional impairment). Toxicity was recorded prospectively
weekly up to and including week 10.
If grade III or IV DLT was observed in two or less patients in a
cohort of six, then a further cohort was treated at the next dose
level. The maximum tolerated dose (MTD) was defined if three or
more of six patients experienced DLT. Once the MTD was defined,
the preceding dose level would then be expanded and a total of 20
patients treated at the recommended dose.
The primary end points of the study were acute grade III/IV
toxicity and compliance with the planned doses of chemotherapy
and radiotherapy. Secondary end points included the histopatho-
logical complete response (pCR) rate, resectability rate, local
recurrence rate and late morbidity.
Eligibility criteria
Eligibility criteria included histologically confirmed adenocarci-
noma, WHO performance status 0–2 and no evidence of
metastatic disease using chest X-ray and abdominopelvic CT.
Acceptable haematological and renal function was required:
neutrophils 41.5 10
9l
 1, platelets X100 10
9l
 1, and serum
creatinine o1.25  the institutions upper limit of normal range.
Patients with locally advanced, biopsy-proven carcinoma of the
rectum were included either on the basis of fixity on digital rectal
examination (DRE), T4 stage on pelvic CT or when MRI
demonstrated a high risk of involvement of the CRM. The method
used to define locally advanced disease, the distance of the inferior
tumour border to the anal verge (cm) and intended surgical
procedure were also recorded.
Patients were excluded from the study because of prior
chemotherapy or pelvic radiation, lack of efficient contraception
or pregnancy, inflammatory bowel disease and cardiac conditions
that would deter the safe delivery of 5FU. Patients having six
episodes of stool per day or who were incontinent of faeces were
also excluded.
Pelvic radiation
Using information from clinical examination and pelvic MRI, the
gross tumour volume (GTV) was defined using a CT planning
scan. To derive the planning target volume (PTV), margins were
added to the GTV according to the radiation planning diagrams
(3cm laterally, superiorly and inferiorly, 2cm anteriorly) included
in the protocol, with the exception of the posterior border, which
was always located on the most posterior aspect of the bony
sacrum. Patients were treated prone with a full bladder using either
Oxaliplatin 
170 mg m–2
150 mg m–2 
130 mg m–2
85 mg m–2
↓↓ ↓↓↓ ↓↓ ↓↓↓ ↓↓ ↓↓↓ ↓↓ ↓↓↓ ↓↓ ↓↓↓
Radiotherapy – 3/4 field planned volume 45 Gy in 25 fractions 
Figure 1 Chemoradiation schedule. & Oxaliplatin at dose levels shown on days 2 and 30 prior to LV, 5FU; ,L V2 0m gm
 2 bolus on days 1–5 and 29–
33; ↓, 5FU 350mgm
 2 60-min infusion on days 1–5 and 29–33; k, radiotherapy 1.8Gy per fraction.
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sa three- or four-field technique. A total dose of 45Gy was delivered
to the International Commission on Radiation Units intersection
point using 25 daily fractions of 1.8Gy. Orthogonal film simulation
was performed with opacification of the small bowel using barium
sulphate 300ml with gastrograffin 20ml.
Surgery and histopathology
Surgery was recommended to take place 6–10 weeks after
completion of CRT. Histopathological examination of the resected
specimen was performed according to the technique described by
Quirke (Birbeck and Quirke, 1999). The CRM is considered
involved if microscopic tumour is present at or less than 1mm
from the circumferential or radial resection margin.
Assessment during and after treatment
Full blood count, urea creatinine and electrolytes, and liver
function tests and acute toxicity scores were assessed prospectively
on weeks 1–6 and 10. On completion of CRT, follow-up
appointments were given at 3, 6 12, 24 and 36 months to assess
tumour recurrence and late toxicity.
For the purposes of this study, local recurrence has been defined
in patients who have had a complete macroscopic resection as
evidence of either an intraluminal or extraluminal mass below the
sacral promontory and biopsy-proven adenocarcinoma, or CEA
abnormal with or without the presence of metastases. Radiological
evidence of interval enlargement of the mass (minimum interval of
6 weeks) was required if based on CT scans alone (biopsy negative
and CEA normal).
RESULTS
Between February 1999 and October 2001, a total of 32 patients
were recruited from four centres: 24 males, eight females, median
age 60 years (range 31–79). Their tumour characteristics are
summarised in Table 1. Five patients were excluded from the
prospective assessment of DLT and dose recommendations. Two
patients failed to start treatment, two patients refused the day 30
dose of oxaliplatin, but had not experienced DLT, and one patient
died during CRT of an intestinal perforation considered unrelated
to study therapy.
Protocol compliance
During the dose escalation phase, full compliance was achieved (no
reduction in planned dose or duration of treatment) for radiation
dose or chemotherapy dose at 85mgm
 2, whereas one out of six
patients at 130mgm
 2 required interruption of radiation and
three out of six patients at 150mgm
 2 required chemotherapy
dose reduction (two of which also had radiotherapy interrupted).
The median field size, in all patients, for the posterior/anterior
field was 15.1cm (range 10.5–20.1) height 13.9cm (range 11.4–
18.0) width, and for the lateral/oblique fields 15.4cm (range 11.5–
20.0) height 13.4cm (range 10.5–20.5) width. In all, 28 out of 32
patients proceeded to have radical surgery; the median time to
surgery was 9 weeks (interquartile range 8–11 weeks). Information
on pathological status was available on 27 patients due to the loss
of one surgical specimen.
Acute toxicity
The acute grade III/IV toxicity experienced is summarised for the
three dose levels and the subsequent patients treated in the
expanded cohort at 130mgm
 2 in Table 2. During the dose
escalation phase, DLT was seen in two out of six patients at
85mgm
 2 and in four out of six patients at 150mgm
 2. In view of
the toxicity seen at 150mgm
 2, the decision was made to stop
recruitment to this dose level and to expand the 130mgm
 2 dose
level to the planned total of 20 patients.
The most common toxicity was diarrhoea; this occurred in 10
patients, eight grade 3 and two grade 4. Three patients had grade 3
neurotoxicity, 15 others reported this toxicity at grade 1 or 2, all of
these events resolved within 4weeks following treatment. Haema-
tological toxicity was rare, with only one grade 3 anaemia reported
at the 150mgm
 2 dose level.
Response to treatment
Tumour downstaging was defined by comparing clinical TN stage
prior to treatment (as determined by pelvic MRI) with histopatho-
logical stage post surgery. Chemoradiation achieved downstaging
in 8 out of 27 (30%) of patients. The pathological stages at surgery
were T0N0¼2, T1NO¼1, T0N1¼1, T1N1¼1, T2N0¼3,
T3N0¼9, T3N1¼6, T3NX¼1 and T4N0¼3. It can be seen that
CRT achieved a complete pathological response in 2 out of 27 (7%)
cases who proceeded to surgery (Table 3) and 2 out of 32 (6%) of
Table 1 Patient and tumour characteristics
Characteristic n¼32
Median age (range) 60 (31–79)
Male:female 24:8
WHO status 0:1:2 9:21:2
Site of tumour
Upper:mid:lower 4:12:16
Local extent
Fixed/unresectable 16
Locally advanced on MRI 16
WHO¼World Health Organisation; MRI¼magnetic resonance imaging.
Table 2 Acute toxicity
Oxaliplatin dose (mgm
 2) 85 130
a 150 All
No. of patients 6 6/14 6 32
Patients with DLT 2 2/3 4 11
Gd 3 diarrhoea 2 0/3 3 8
Gd 4 diarrhoea 0 2/0 0 2
Gd 3 neurological
b 0 1/0 2 3
Gd 3 anaemia 0 0/0 1 1
aThe figures in this column indicate the numbers in the initial six patients treated at
this dose level, followed by the numbers in the expanded group once the MDT was
determined.
bDefined as functional impairment using the Sanofi oxaliplatin
neurotoxoicity score.
Table 3 Pathological response
Oxaliplatin dose (mgm
 2) 85 130 150 All (%)
Number of patients 6 20 6 32
Number operated 6 19
a 3
b 28
pCR 0/6 2/19 0/2 2/27 (7%)
pT0–2 pN0 2/6 6/19 0/2 8/27 (30%)
Tmic 1/6 2/19 0/2 3/27 (11%)
 ve CRM
c 5/6 15/19 2/2 22/27 (81%)
aOne patient inoperable.
bOne inoperable, one unfit for surgery, one patient refused,
one specimen lost.
c ve CRM¼tumour clearance of more than 1mm from
circumferential resection margin, pCR¼histopathological complete response;
Tmic¼microscopic disease only detected in surgical specimen; CRM¼circumfer-
ential resection margin.
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sthe whole group. Histopathology also demonstrated microscopic
disease only (Tmic) in 3 out of 27 (11%), patients, pCRþTmic in 5
out of 27 (19%), pT0–2 in 6 out of 27 (22%) and histologically
confirmed (41mm) clear CRM in 22 out of 27 (81%).
Surgery
Of the 32 evaluable patients, four did not proceed to surgery due to
the presence of metastatic disease (two), patient refusal (one) and
unfitness for surgery (one) (Figure 2). All patients had a
preliminary clinical assessment by their surgeon at entry, and
were categorised on the basis of height of the cancer from the anal
verge as requiring an abdominoperineal resection (APR) or
anterior resection (AR). Of the 28 surgical procedures, 15 had an
APR, two of which had initially been assessed as requiring an AR,
the remaining 13 had APR as expected (one with cystectomy). Ten
patients had an AR, six of which had been anticipated and four
that had been expected to require an APR. One patient had a
Hartman’s procedure after an initial assessment of an APR. Two
additional patients required exenterative surgery (one initially
assessed to require this procedure and one initially assessed as
requiring AR). There were no unexpected post operative
complications or deaths.
Local recurrence and survival
The strength of this study is that the median follow-up is 41
months (range 6–64 months) for all patients and 41 months for
surviving patients (range 31–64 months). In all, 23 of the 32
patients remain alive at the time of writing. Of the 22 patients
having complete surgical clearance of tumour (CRM ve) six
relapsed (one local, four distant, and one at local and distant sites),
of which four subsequently died of disease (Figure 2 and Table 4).
Of the five incomplete resections (CRMþve) only one patient is
alive without disease (45 months from the start of treatment); the
remaining four progressed: one local, one distant, and two local
and distant, both of whom died. Three of the four patients who
were not resected died and the fourth patient is alive at 45 months
with a pelvic mass. The DFS for the whole group at 3 years is 62%
(95% CI 43–77%) (see Figure 3) and 82% (95% CI 58–93%) for
those having had a complete resection. All six patients who had
T0–2 NO tumours remain alive and disease free. Of the 21 patients
with T3/4 NO/1 or T0–2 N1 disease, 11 are alive and disease free,
four are alive with disease and six have died due to disease.
Late effects
Severe late effects were uncommon, despite the combination of
oxaliplatin and radiotherapy. Grade 3 late toxicity was reported in
five patients (85mgm
 2; one diarrhoea, 130mgm
 2; one tenesmus
and diarrhoea, 150mgm
 2; one tenesmus and one bleeding and
pain). As four of the five patients had relapsed disease, it is unclear
whether the symptoms reflect radiation or recurrence.
DISCUSSION
The objective of this study was to determine the MTD of
oxaliplatin in combination with pelvic radiotherapy and low-dose
folinic acid and a 60-min infusion of 5FU with 45Gy of
Evaluable patients* 
n=32  Unresectable 
n=2  
(One died, One alive with disease) 
Potentially  curative resection 
n=28** 
Refused/unfit for surgery
n=2  
(both died) 
CRM –ve (R0) 
n=22 
16 alive disease-free
Two alive with disease 
Four died 
CRM +ve (R1) 
n=5 
One alive disease-free 
Two alive with disease 
Two died 
Figure 2 Patient outcome. *Five unassessable patients not included; one died, two did not start treatment, two refused week 5 chemo; **one specimen
lost.
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Months  0 20 40 60 
Nos. at risk  32  26  12    4 
Figure 3 Disease-free survival – all patients.
Table 4 Pattern of recurrence following radical resection
Oxaliplatin dose (mgm
 2) 85 130 150 All
Number of patients 6 19 3 28
Any disease 3 7 1 11/27 (41%)
Local recurrence 1 3 0 4/27 (15%)
Distant metastases 3 5 1 9/27 (33%)
Death 3 3 1 7/27 (26%)
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sradiotherapy given preoperatively in patients with locally ad-
vanced rectal cancer. The eligibility criteria used in this study
define a relatively homogeneous group of very locally advanced
rectal cancer. The MTD of oxaliplatin combined with pelvic
radiotherapy (using relatively large field size) has been defined as
150mgm
 2 on days 2 and 30, and the recommended dose as
130mgm
 2. The dose intensity of oxaliplatin (260mgm
 2 over 5
weeks) in the present study is similar to that achieved by Freyer
et al (2001) using a day 1 and 29 schedule and higher than that
used (200mgm
 2) in a recent German study (Ro ¨del et al, 2003).
The histologically confirmed RO (CRM –ve) resection rate of
81% is high for this locally advanced group (Bosset et al, 2005;
Gerard et al, 2005). In this study, only two patients had
unresectable disease and only three patients had partial pelvic
clearances. In contrast, the German CAO/ARO/AIO – 94 study
(Ro ¨del et al, 2003) reported 8 out of 31 patients who underwent
exenteration or resection of adjacent organs.
This study did not seek to assess the impact or control the use of
postoperative chemotherapy. Only 7% of the study group received
such treatment and this consisted of 5FU LV. The EORTC 22921
trial (Bosset et al, 2005) did not demonstrate a significant impact
on outcome when postoperative chemotherapy was compared with
no further treatment when given after preoperative CRT, and it is
unlikely that the use of postoperative chemotherapy will have
significantly altered the outcome of this study.
Enthusiasm for preoperative CRT in the management of rectal
cancer is increasing. The German CAO/ARO/AIO – 94 study
protocol has convincingly shown improved locoregional control
and reductions in acute and late toxicity with preoperative CRT
(Sauer et al, 2004) vs postoperative combined modality treatment
for stage II/III resectable rectal cancer. The rationale for
preoperative CRT is attractive, as it combines early systemic
chemotherapy treatment simultaneously with a locoregional
treatment.
In addition, over the past decade, nonrandomised studies have
confirmed that preoperative treatment with radiotherapy (Wag-
man et al, 1998) can facilitate sphincter-sparing options. A study
from Lyon compared immediate and delayed surgery after
preoperative radiotherapy (Francois et al, 1999). Sphincter
preservation was achieved in 79% of patients with a long interval
(4–6 weeks) following radiotherapy, compared with 69% of
patients where the interval was only short (2 weeks). A further
report (Glehen et al, 2003) documents that, with a median follow-
up of 6.3 years, no differences were found in the degree of local
control, overall survival, morbidity, anal function or surgical
complications between the two groups. The addition of che-
motherapy to radiotherapy can be used to shrink the primary
tumour further and facilitate sphincter-sparing options. Impress-
ive results appear to have been achieved in phase II studies with
CRT (Grann et al, 1997; Rullier et al, 2001) and long-term follow-
up has confirmed an excellent outcome if there is marked
shrinkage of the primary tumour (Ruo et al, 2002).
There have been several reported phase I and II studies
integrating oxaliplatin into fluoropyrimidine-based CRT schedules
(Ge ´rard et al, 2003; Gambacorta et al, 2004; Aschele et al, 2005).
There are, however, important differences between these and the
current study. Gambacorta et al (2004) evaluated the combination
of raltitrexed and oxaliplatin with 50.4Gy radiation. Aschele et al
(2005) used a weekly schedule of oxaliplatin combined with
continuous infusion 5FU and 50.4Gy irradiation. Ge ´rard et al
(2003) used the same doses of 5FU/LV as this study, but delivered
this as a continuous infusion over 24h for days 1–5 and 29–33,
but did not determine the MTD of the combination of oxaliplatin
on days 1 and 29 when added to 5FU/LV and radiation.
The present study has a number of important differences from
the above studies. Firstly, the total dose of radiation was fixed at
45Gy, a total dose that is 10% lower than the other studies. This
dose might be expected to be associated with a lower incidence of
late complications. Secondly, this study formally determined the
MTD and recommended dose of oxaliplatin when added to a
validated CRT fluoropyrimidine schedule used in two recent phase
III trials (Bosset et al, 2005; Gerard et al, 2005). Finally, this study
reports outcome data that is relatively mature (41-month median
follow-up) and is also based on the circumferential margin status.
We are not aware that any other combination CRT study has
reported such data. This is superior to retrospective data with 5FU
CRT (Sebag-Montefiore et al, 2005). Now that there is clear
evidence that locoregional control is improved by the addition of
the 5FU/LV regimen used in this study to 45Gy of pelvic radiation,
there is a strong rationale for future trials to establish the benefit of
the addition of oxaliplatin.
Further studies by our group, including the CORE study (DSM
personal communication) abstract submitted to ECCO and
Socrates studies (Gerard et al, 2005; Glynne-Jones et al, 2003,
2005), will further clarify the potential of using oxaliplatin in
combination with oral fluoropyrimidines and radiotherapy in
locally advanced rectal cancer. These data suggest that combina-
tion radiochemotherapy leads to improved early histopathological
outcome measures. This has the potential to translate into
improved long-term outcomes in rectal cancer, both in terms of
quality of life and overall survival, and will be tested in current and
future phase III trials.
In conclusion, the MTD with oxaliplatin is confirmed as
150mgm
 2 given on days 2 and 30, when added to the described
5FU LV and 45Gy radiation preoperatively. The recommended
dose of oxaliplatin in this setting is 130mgm
 2. This dose is
associated with high compliance and manageable acute toxicity,
and appears to offer significant shrinkage and pathological
downstaging even for bulky T3/T4 cancers considered unresect-
able. In the adjuvant setting, the addition of oxaliplatin to 5FU/LV
significantly improves DFS (Andre ´ et al, 2004) and may reduce the
incidence of micrometastases. There are no concerns regarding
excess late morbidity from this combination, and we therefore
recommend testing this dose in future phase II/III studies.
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